These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

361 related items for PubMed ID: 19300416

  • 1. Quantitative detection of cytokeratin 20 mRNA in urine samples as diagnostic tools for bladder cancer by real-time PCR.
    Guo B, Luo C, Xun C, Xie J, Wu X, Pu J.
    Exp Oncol; 2009 Mar; 31(1):43-7. PubMed ID: 19300416
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Detection of circulating gastric cancer cells in peripheral blood using real time quantitative RT-PCR.
    Koga T, Tokunaga E, Sumiyoshi Y, Oki E, Oda S, Takahashi I, Kakeji Y, Baba H, Maehara Y.
    Hepatogastroenterology; 2008 Mar; 55(84):1131-5. PubMed ID: 18705345
    [Abstract] [Full Text] [Related]

  • 4. Quantitative detection of cytokeratin 20 mRNA expression in bladder carcinoma by real-time reverse transcriptase-polymerase chain reaction.
    Christoph F, Müller M, Schostak M, Soong R, Tabiti K, Miller K.
    Urology; 2004 Jul; 64(1):157-61. PubMed ID: 15245962
    [Abstract] [Full Text] [Related]

  • 5. A prospective evaluation of the diagnostic and potential prognostic utility of urinary human telomerase reverse transcriptase mRNA in patients with bladder cancer.
    Bowles L, Bialkowska-Hobrzanska H, Bukala B, Nott L, Razvi H.
    Can J Urol; 2004 Dec; 11(6):2438-44. PubMed ID: 15636669
    [Abstract] [Full Text] [Related]

  • 6. [Clinical value of combined detection with urinary bladder cancer antigen, hyaluronic acid and cytokeratin 20 in diagnosis of bladder cancer].
    Pu XY, Wang ZP, Chen YR, Wu YL, Wang HP, Wang XH.
    Ai Zheng; 2008 Sep; 27(9):970-3. PubMed ID: 18799038
    [Abstract] [Full Text] [Related]

  • 7. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
    Eissa S, Swellam M, Sadek M, Mourad MS, El Ahmady O, Khalifa A.
    J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
    [Abstract] [Full Text] [Related]

  • 8. [Detection of cytokeratin20 mRNA in peripheral blood from colonic cancer patients by fluorescence quantitative polymerase chain reaction].
    Wang ZC, Wang C, Zeng QG.
    Zhonghua Zhong Liu Za Zhi; 2007 Aug; 29(8):600-3. PubMed ID: 18210880
    [Abstract] [Full Text] [Related]

  • 9. Molecular staging of bladder cancer with RT-PCR assay for CK20 in peripheral blood, bone marrow and lymph nodes: comparison with standard histological staging.
    Ribal MJ, Mengual L, Marín M, Algaba F, Ars E, Fernández PL, Oliva R, Villavicencio H, Alcaraz A.
    Anticancer Res; 2006 Aug; 26(1A):411-9. PubMed ID: 16475726
    [Abstract] [Full Text] [Related]

  • 10. Expression of cytokeratin 20 in urinary cytology of patients with bladder carcinoma.
    Klein A, Zemer R, Buchumensky V, Klaper R, Nissenkorn I.
    Cancer; 1998 Jan 15; 82(2):349-54. PubMed ID: 9445193
    [Abstract] [Full Text] [Related]

  • 11. The simultaneous use of telomerase, cytokeratin 20 and CD4 for bladder cancer detection in urine.
    Siracusano S, Niccolini B, Knez R, Tiberio A, Benedetti E, Bonin S, Ciciliato S, Pappagallo GL, Belgrano E, Stanta G.
    Eur Urol; 2005 Mar 15; 47(3):327-33. PubMed ID: 15716196
    [Abstract] [Full Text] [Related]

  • 12. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
    Kumar A, Kumar R, Gupta NP.
    Jpn J Clin Oncol; 2006 Mar 15; 36(3):172-5. PubMed ID: 16520358
    [Abstract] [Full Text] [Related]

  • 13. [Expression and clinical significance of nuclear matrix protein 22 and cytokeratin 18 in transitional cell carcinoma of the bladder].
    Song JW, DU LL, Zhao XW, Jing JX, Han CZ, Cui Y, Liu JW, Hao HL, Wang ZG, Mi ZG.
    Zhonghua Zhong Liu Za Zhi; 2009 Apr 15; 31(4):274-7. PubMed ID: 19615282
    [Abstract] [Full Text] [Related]

  • 14. Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder.
    Shariat SF, Herman MP, Casella R, Lotan Y, Karam JA, Stenman UH.
    Eur Urol; 2005 Sep 15; 48(3):424-31. PubMed ID: 15963628
    [Abstract] [Full Text] [Related]

  • 15. Prognostic value of cytology, nuclear matrix protein 22 (NMP22) test, and urinary bladder cancer II (UBC II) test in early recurrent transitional cell carcinoma of the bladder.
    Kibar Y, Goktas S, Kilic S, Yaman H, Onguru O, Peker AF.
    Ann Clin Lab Sci; 2006 Sep 15; 36(1):31-8. PubMed ID: 16501234
    [Abstract] [Full Text] [Related]

  • 16. Quantitative real-time RT-PCR detection for survivin, CK20 and CEA in peripheral blood of colorectal cancer patients.
    Shen C, Hu L, Xia L, Li Y.
    Jpn J Clin Oncol; 2008 Nov 15; 38(11):770-6. PubMed ID: 18845519
    [Abstract] [Full Text] [Related]

  • 17. Urinary cytokeratin 20 mRNA expression has the potential to predict recurrence in superficial transitional cell carcinoma of the bladder.
    Christoph F, Weikert S, Wolff I, Schostak M, Tabiti K, Müller M, Miller K, Schrader M.
    Cancer Lett; 2007 Jan 08; 245(1-2):121-6. PubMed ID: 16473461
    [Abstract] [Full Text] [Related]

  • 18. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice.
    May M, Hakenberg OW, Gunia S, Pohling P, Helke C, Lübbe L, Nowack R, Siegsmund M, Hoschke B.
    Urology; 2007 Sep 08; 70(3):449-53. PubMed ID: 17688921
    [Abstract] [Full Text] [Related]

  • 19. Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology.
    Shariat SF, Casella R, Wians FH, Ashfaq R, Balko J, Sulser T, Gasser TC, Sagalowsky AI.
    Eur Urol; 2004 Mar 08; 45(3):304-13; author reply 313. PubMed ID: 15036675
    [Abstract] [Full Text] [Related]

  • 20. Urine concentration of nuclear matrix protein 22 for diagnosis of transitional cell carcinoma of bladder.
    Jamshidian H, Kor K, Djalali M.
    Urol J; 2008 Mar 08; 5(4):243-7. PubMed ID: 19101898
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.